Indications for Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery

Guideline Objective

To determine evidence-based indications for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC).

Patient Population

Adults (≥18 years old) with a diagnosis of mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian, or primary peritoneal carcinoma.

Intended Guideline Users

This guideline is intended for clinicians involved in the care of patients with mesothelioma, appendiceal (including appendiceal mucinous neoplasm), colorectal, gastric, ovarian, or primary peritoneal carcinoma.

Research Questions

1. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with ovarian cancer? If so, which patients derive greater benefit?
2. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with peritoneal colorectal carcinomatosis? If so, which patients derive greater benefit?
3. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with gastric peritoneal carcinomatosis ? If so, which patients derive greater benefit?
4. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with peritoneal mesothelioma? If so, which patients derive greater benefit?
5. Does the use of HIPEC with CRS provide better outcomes (i.e., improved survival and reduced adverse events) than current oncological management of patients with disseminated mucinous neoplasm of the appendix? If so, which patients derive greater benefit?